A Neutrophil Timer Coordinates Immune Defense and Vascular Protection.


Journal

Immunity
ISSN: 1097-4180
Titre abrégé: Immunity
Pays: United States
ID NLM: 9432918

Informations de publication

Date de publication:
19 02 2019
Historique:
received: 24 08 2018
revised: 23 11 2018
accepted: 02 01 2019
pubmed: 3 2 2019
medline: 14 8 2019
entrez: 3 2 2019
Statut: ppublish

Résumé

Neutrophils eliminate pathogens efficiently but can inflict severe damage to the host if they over-activate within blood vessels. It is unclear how immunity solves the dilemma of mounting an efficient anti-microbial defense while preserving vascular health. Here, we identify a neutrophil-intrinsic program that enabled both. The gene Bmal1 regulated expression of the chemokine CXCL2 to induce chemokine receptor CXCR2-dependent diurnal changes in the transcriptional and migratory properties of circulating neutrophils. These diurnal alterations, referred to as neutrophil aging, were antagonized by CXCR4 (C-X-C chemokine receptor type 4) and regulated the outer topology of neutrophils to favor homeostatic egress from blood vessels at night, resulting in boosted anti-microbial activity in tissues. Mice engineered for constitutive neutrophil aging became resistant to infection, but the persistence of intravascular aged neutrophils predisposed them to thrombo-inflammation and death. Thus, diurnal compartmentalization of neutrophils, driven by an internal timer, coordinates immune defense and vascular protection.

Identifiants

pubmed: 30709741
pii: S1074-7613(19)30002-0
doi: 10.1016/j.immuni.2019.01.002
pii:
doi:

Substances chimiques

CXCR4 protein, human 0
Chemokine CXCL2 0
Receptors, CXCR4 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Pagination

390-402.e10

Commentaires et corrections

Type : CommentIn
Type : ErratumIn

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

José M Adrover (JM)

Area of Developmental and Cell Biology, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.

Carlos Del Fresno (C)

Area of Myocardial Pathophysiology, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.

Georgiana Crainiciuc (G)

Area of Developmental and Cell Biology, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.

Maria Isabel Cuartero (MI)

Unidad de Investigación Neurovascular, Department of Pharmacology, Faculty of Medicine, Universidad Complutense; Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain.

María Casanova-Acebes (M)

Area of Developmental and Cell Biology, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain; Present address: Tisch Cancer Institute, Mount Sinai School of Medicine, New York City, New York, USA.

Linnea A Weiss (LA)

Area of Developmental and Cell Biology, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain; Present address: Centro Nacional de Biotecnología, Madrid, Spain.

Hector Huerga-Encabo (H)

Immunology Unit, Department of Experimental and Health Sciences, Pompeu Fabra University, Barcelona.

Carlos Silvestre-Roig (C)

Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximillians-Universität München; German Centre for Cardiovascular Research (DZHK), partner site Munich Heart Alliance, Munich, Germany.

Jan Rossaint (J)

Department of Anesthesiology, Intensive Care, and Pain Medicine, University of Münster, Germany.

Itziar Cossío (I)

Area of Developmental and Cell Biology, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.

Ana V Lechuga-Vieco (AV)

Area of Myocardial Pathophysiology, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.

Jaime García-Prieto (J)

Area of Myocardial Pathophysiology, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.

Mónica Gómez-Parrizas (M)

Area of Myocardial Pathophysiology, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.

Juan A Quintana (JA)

Area of Developmental and Cell Biology, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.

Ivan Ballesteros (I)

Area of Developmental and Cell Biology, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.

Sandra Martin-Salamanca (S)

Area of Developmental and Cell Biology, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.

Alejandra Aroca-Crevillen (A)

Area of Developmental and Cell Biology, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.

Shu Zhen Chong (SZ)

Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A(∗)STAR), Biopolis, Singapore.

Maximilien Evrard (M)

Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A(∗)STAR), Biopolis, Singapore.

Karl Balabanian (K)

Inserm Unité Mixte de Recherche (UMR) S996, Université Paris-Sud, Laboratory of Excellence in Research on Medication and Innovative Therapeutics, Clamart, France.

Jorge López (J)

Department of Immunology, Instituto de Investigación Sanitaria Princesa, Hospital Universitario de La Princesa, Madrid, Spain.

Kiril Bidzhekov (K)

Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximillians-Universität München.

Françoise Bachelerie (F)

Inserm Unité Mixte de Recherche (UMR) S996, Université Paris-Sud, Laboratory of Excellence in Research on Medication and Innovative Therapeutics, Clamart, France.

Francisco Abad-Santos (F)

Department of Clinical Pharmacology, Instituto Teófilo Hernando, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa, Madrid, Spain.

Cecilia Muñoz-Calleja (C)

Department of Immunology, Instituto de Investigación Sanitaria Princesa, Hospital Universitario de La Princesa, Madrid, Spain.

Alexander Zarbock (A)

Department of Anesthesiology, Intensive Care, and Pain Medicine, University of Münster, Germany.

Oliver Soehnlein (O)

Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximillians-Universität München; German Centre for Cardiovascular Research (DZHK), partner site Munich Heart Alliance, Munich, Germany.

Christian Weber (C)

Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximillians-Universität München; Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, the Netherlands.

Lai Guan Ng (LG)

Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A(∗)STAR), Biopolis, Singapore.

Cristina Lopez-Rodriguez (C)

Immunology Unit, Department of Experimental and Health Sciences, Pompeu Fabra University, Barcelona.

David Sancho (D)

Area of Myocardial Pathophysiology, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.

María A Moro (MA)

Unidad de Investigación Neurovascular, Department of Pharmacology, Faculty of Medicine, Universidad Complutense; Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain.

Borja Ibáñez (B)

Area of Myocardial Pathophysiology, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain; CIBER de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain; Department of Cardiology, Instituto de Investigación Sanitaria (IIS)-Fundación Jiménez Díaz, Madrid, Spain.

Andrés Hidalgo (A)

Area of Developmental and Cell Biology, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain; Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximillians-Universität München. Electronic address: ahidalgo@cnic.es.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH